香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本通告全部或任何部份內容而產生或因倚賴該等內容而引致的任 何損失承擔任何責任。 BOCOM INTERNATIONAL HOLDINGS COMPANY LIMITED （於香港註冊成立的有限公司） （股份代號：3329） 股東特別大會通告 茲通告交銀國際控股有限公司（「本公司」）謹訂於2026 年3 月4 日（星期三） 上午十一時正，假座香港德輔道中6 8 號萬宜大廈9 樓1 號會議室及通過網上平台 https://meetings.computershare.com/BOCOMI_2026EGM 舉行股東特別大會（「股東特別 大會」），旨在考慮及酌情通過下列決議案（不論有否予以修訂）。本股東特別大會通告 未明確界定之詞彙及表達與本公司日期為2026年2月10日的通函（「該通函」）所界定者 具有相同涵義。 普通決議案 1. 為增強與股東的聯繫並提升股東參與度，股東特別大會將是一次混合會議。本公司鼓勵股東通過電 子設施行使出席股東特別大會和投票的權利。 通過登錄專用網上平台 htt ...

此乃要件 請即處理 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢 閣下之持牌證券交易商、註冊證券機構、銀行經理、 律師、專業會計師或其他專業顧問獲取獨立意見。 閣下如已將名下之交銀國際控股有限公司的全部股份出售或轉讓，應立即將本通函及隨附之代表委任表格送交買主或 承讓人，或經手買賣或轉讓之銀行經理、持牌證券交易商或註冊證券機構或其他代理商，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示，概不對因本通函全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 BOCOM INTERNATIONAL HOLDINGS COMPANY LIMITED （於香港註冊成立的有限公司） （股份代號：3329） 有關行政及非行政職能支持服務共享框架協議 之持續關連交易 及 股東特別大會通告 獨立董事委員會及獨立股東之 獨立財務顧問 ALTUS CAPITAL LIMITED ቺᑼၗԖज़Ϧљ 除文義另有所指外，本封面頁所使用詞彙與本通函所界定者具有相同涵義。 董事會函件載於本通函第4頁至16頁。獨立董事 ...

格隆汇2月6日丨交银国际(03329.HK)公告，于2026年2月5日，Preferred Investment于场外市场以购买价 约99.599美元收购本金额为10,000,000美元的CDBALF票据II，代价约为9,959,900美元(相当于约 78,185,215港元)。 ...

交银国际(03329)发布公告，于2026年2月5日，Preferred Investment于场外市场以购买价约99.599美元收 购本金额为1000万美元的CDBALF票据II，代价约为995.99万美元(相当于约7818.52万港元)。 ...

智通财经APP讯，交银国际(03329)发布公告，于2026年2月5日，Preferred Investment于场外市场以购买 价约99.599美元收购本金额为1000万美元的CDBALF票据II，代价约为995.99万美元(相当于约7818.52万 港元)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 有關收購票據之 須予披露交易 收購 於2026年2月5日，Preferred Investment於場外市場以購買價約99.599美元收購本金額 為10,000,000美元的CDBALF票據II，代價約為9,959,900美元（相當於約78,185,215港 元）。 上市規則之涵義 BOCOM INTERNATIONAL HOLDINGS COMPANY LIMITED 交銀國際控股有限公司 （於香港註冊成立的有限公司） （股份代號：3329） 由於先前收購及收購乃於十二個月期間內作出，故根據上市規則第14.22條，該等事項 應合併為本公司的一系列交易。由於有關該等收購的一項或多項適用百分比率合併計 算後低於25%但高於5%，該等收購構成本公司須予披露交易，因此須遵守上市規則第 十四章項下的通知及公告規定。 收購 於2026年2月5日，Preferred Investment於場外市場以購買價約99.5 ...

Core Viewpoint - The report from交银国际 indicates a slight decrease in the proportion of domestic investors holding pharmaceutical stocks through the Hong Kong Stock Connect since the fourth quarter of last year, while foreign investment has increased, particularly in innovative drugs and leading CXO companies benefiting from demand recovery [1] Group 1: Investment Trends - Domestic investors' holdings in pharmaceutical stocks via Hong Kong Stock Connect have slightly decreased [1] - Foreign investors have increased their positions, particularly in innovative drug companies and leading CXO firms [1] Group 2: Investment Recommendations - The report suggests focusing on differentiated platforms such as small nucleic acids, long-acting formulations, invivo CAR-T, and new generation ADC/XDC, as well as disease areas like autoimmune, metabolic, and CNS [1] - The pharmaceutical sector is expected to maintain a stable upward trend this year, although short-term volatility may occur [1] Group 3: Stock Selection Criteria - Investors are advised to examine company fundamentals and valuations to identify undervalued stocks, such as 三生制药, 和黄医药, and 劲方医药, which have rich catalysts not yet reflected in their valuations [1] - CXO segment leaders, like 药明合联, are expected to benefit from a favorable downstream environment and improved financing conditions [1] - Sub-sectors such as hospitals, medical devices, and diagnostics are anticipated to see regulatory uncertainties gradually easing along with positive policy expectations [1]

Core Viewpoint - The Hang Seng Healthcare Index has declined by 3.3% this week, underperforming the market, with a slight decrease in domestic investors' holdings of pharmaceutical stocks through the Hong Kong Stock Connect since the fourth quarter of last year, while foreign investment has increased [1] Group 1: Market Performance - The Hang Seng Healthcare Index has experienced a cumulative drop of 3.3% this week [1] - Domestic investors' holdings of pharmaceutical stocks via the Hong Kong Stock Connect have slightly decreased [1] - Foreign investment in the sector has increased, particularly in innovative drugs and leading CXO companies benefiting from demand recovery [1] Group 2: Investment Recommendations - The company suggests focusing on differentiated platforms such as small nucleic acids, long-acting formulations, invivo CAR-T, and new generation ADC/XDC in the pharmaceutical business development this year [1] - The sector is expected to maintain a stable upward trend this year, although short-term volatility may occur [1] - Investors are advised to examine company fundamentals and valuations to identify undervalued stocks, such as 3SBio (01530), Hutchison China MediTech (00013), and Genscript Biotech (02595) [1] - CXO segment leaders like WuXi AppTec (02268) may benefit from a favorable downstream environment and improved financing conditions [1] - Sub-sectors such as hospitals, medical devices, and diagnostics may see regulatory uncertainties easing along with positive policy expectations [1]

Core Viewpoint - The announcement by交银国际 (03329) regarding the framework agreement with交通银行 aims to enhance operational efficiency and cost-effectiveness through shared administrative and non-administrative support services [1] Group 1: Agreement Details - The framework agreement is set to commence on February 3, 2026, and will remain effective until December 31, 2028, with an automatic three-year renewal subject to applicable listing rules [1] - The agreement requires independent shareholder approval for the proposed transactions and related annual caps [1] Group 2: Operational Impact - The collaboration with交通银行 is expected to leverage the group's resources, thereby improving overall operational efficiency and reducing operational costs [1] - By integrating various administrative and non-administrative support functions, the company aims to minimize resource duplication and lower fixed investments in infrastructure, systems, and personnel, achieving economies of scale [1]

行政及非行政职能支持服务共享框架协议项下拟进行的交易将使本集团凭借交通银行集团的资源，提升 其整体运营效率及成本效益。通过整合若干行政及非行政支持职能，本集团可减少资源重复及降低对基 础设施、系统及人力的固定投入，从而实现规模经济并降低其运营成本。 智通财经APP讯，交银国际(03329)发布公告，于2026年2月3日，本公司与交通银行订立行政及非行政职 能支持服务共享框架协议，据此，交通银行集团同意向本集团提供行政职能支持服务及非行政职能支持 服务。行政及非行政职能支持服务共享框架协议须自根据适用上市规则获得独立股东批准行政及非行政 职能支持服务共享框架协议项下拟进行的交易及相关建议年度上限之日起生效至2028年12月31日止(包 括首尾两日)，并且此后连续三年将自动续期，惟须遵守届时适用上市规则的规定。 ...